奥克列珠单抗
医学
多发性硬化
小学(天文学)
梅德林
物理医学与康复
内科学
免疫学
天文
政治学
物理
法学
淋巴瘤
美罗华
作者
Thomas E. Williams,Jeremy Chataway
标识
DOI:10.1038/s41582-022-00724-8
摘要
Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS). However, a new study suggests that other immunomodulatory disease-modifying therapies that are often used to treat relapsing forms of multiple sclerosis could be effective in people with PPMS who have evidence of active inflammatory disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI